Search Results - "Burmester, Gerd R"

Correction to: Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients.

Authors: Alten, Rieke Burmester, Gerd R. Matucci-Cerinic, Marco et al.

Source: Rheumatology & Therapy. Feb2026, Vol. 13 Issue 1, p293-297. 5p.

Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials.

Authors: Burmester, Gerd R. Stigler, Jayne Rubbert-Roth, Andrea et al.

Source: Rheumatology & Therapy. Jun2024, Vol. 11 Issue 3, p737-753. 17p.

Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients.

Authors: Alten, Rieke Burmester, Gerd R. Matucci-Cerinic, Marco et al.

Source: Rheumatology & Therapy. Dec2023, Vol. 10 Issue 6, p1575-1595. 21p.

Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis.

Authors: Burmester, Gerd R. Coates, Laura C. Cohen, Stanley B. et al.

Source: Rheumatology & Therapy. Oct2023, Vol. 10 Issue 5, p1255-1276. 22p.

The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim Analysis.

Authors: Alten, Rieke Burmester, Gerd R. Matucci-Cerinic, Marco et al.

Source: Rheumatology & Therapy. Feb2023, Vol. 10 Issue 1, p73-93. 21p.

Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials.

Authors: Burmester, Gerd R. Winthrop, Kevin Blanco, Ricardo et al.

Source: Rheumatology & Therapy. Apr2022, Vol. 9 Issue 2, p521-539. 19p.

Correction: Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis.

Authors: Burmester, Gerd R. Coates, Laura C. Cohen, Stanley B. et al.

Source: Rheumatology & Therapy. Feb2024, Vol. 11 Issue 1, p221-222. 2p.

Long-term safety and efficacy of sarilumab with or without background csDMARDs in rheumatoid arthritis.

Authors: Burmester, Gerd R Strand, Vibeke Kivitz, Alan J et al.

Source: Rheumatology. Oct2023, Vol. 62 Issue 10, p3268-3279. 12p.

Sarilumab monotherapy vs sarilumab and methotrexate combination therapy in patients with rheumatoid arthritis.

Authors: Burmester, Gerd R Bykerk, Vivian P Buch, Maya H et al.

Source: Rheumatology. Jun2022, Vol. 61 Issue 6, p2596-2602. 7p.

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.

Authors: Schnitzer TJ Burmester GR Mysler E et al.

Source: Lancet. 8/21/2004, Vol. 364 Issue 9435, p665-674. 10p.

Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial.

Authors: Burmester, Gerd R Buttgereit, Frank Bernasconi, Corrado et al.

Source: Lancet. 7/25/2020, Vol. 396 Issue 10246, p267-276. 10p.

Subjects: Therapeutic use of glucocorticoids, Therapeutic use of monoclonal antibodies, Glucocorticoids, Research, Combination drug therapy, Intravenous therapy, Oral drug administration, Research methodology, Monoclonal antibodies, Evaluation research, Medical cooperation, Drug administration, Comparative studies, Randomized controlled trials, Severity of illness index, Rheumatoid arthritis, Blind experiment, Prednisone, Disease remission, Subcutaneous injections

Geographic Terms: Russia, Italy, France, Serbia, Tunisia, Germany

An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data.

Authors: Burmester, Gerd R. Curtis, Jeffrey R. Yun, Huifeng et al.

Source: Drug Safety. Apr2020, Vol. 43 Issue 4, p379-392. 14p.

Rationale, Design and Methods of the Filgotinib Initial Response Study in Rheumatoid Arthritis (FIRST-RA).

Authors: Pongratz, Georg Alten, Rieke Witte, Torsten et al.

Source: Rheumatology & Therapy. Apr2026, Vol. 13 Issue 2, p435-449. 15p.

Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany.

Authors: Krüger, Klaus Burmester, Gerd R. Wassenberg, Siegfried et al.

Source: Rheumatology International. Jan2019, Vol. 39 Issue 1, p131-140. 10p. 1 Diagram, 1 Chart, 5 Graphs.

On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis.

Authors: Bykerk, Vivian P. Burmester, Gerd R. Combe, Bernard G. et al.

Source: Rheumatology International. Dec2018, Vol. 38 Issue 12, p2225-2231. 7p. 2 Graphs.

Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.

Authors: Burmester, Gerd R. Kremer, Joel M. Van den Bosch, Filip et al.

Source: Lancet. 6/23/2018, Vol. 391 Issue 10139, p2503-2512. 10p.

Subjects: Rheumatoid arthritis treatment, Medication safety, Drug efficacy, Randomized controlled trials, Placebos, Antirheumatic agents, Comparative studies, Research methodology, Medical cooperation, Methotrexate, Research, Rheumatoid arthritis, Evaluation research, Blind experiment, Severity of illness index, Disease progression

Mavrilimumab, a Fully Human Granulocyte–Macrophage Colony‐Stimulating Factor Receptor α Monoclonal Antibody.

Authors: Burmester, Gerd R. McInnes, Iain B. Kremer, Joel M. et al.

Source: Arthritis & Rheumatology. May2018, Vol. 70 Issue 5, p679-689. 11p.

Managing rheumatic and musculoskeletal diseases - past, present and future.

Authors: Burmester, Gerd R. Bijlsma, Johannes W. J. Cutolo, Maurizio et al.

Source: Nature Reviews Rheumatology. Jul2017, Vol. 13 Issue 7, p443-448. 6p.

Novel treatment strategies in rheumatoid arthritis.

Authors: Burmester, Gerd R. Pope, Janet E.

Source: Lancet. 6/10/2017, Vol. 389 Issue 10086, p2338-2348. 11p. 1 Diagram, 1 Graph.

Subjects: Rheumatoid arthritis treatment, Rheumatoid arthritis diagnosis, Drug therapy, Physical therapy, Comorbidity, Methotrexate, Nonsteroidal anti-inflammatory agents, Combination drug therapy, Rheumatoid arthritis

Rheumatoid factors revisited in the age of biologic therapy.

Authors: Avci, Ali Berkant Feist, Eugen Burmester, Gerd R

Source: Rheumatology. 2025 Supplement, pii15-ii24. 10p.